1391 related articles for article (PubMed ID: 17980938)
1. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
3. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
4. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
5. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
8. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
Betts RF
J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
[TBL] [Abstract][Full Text] [Related]
11. Prevention of herpes zoster and its painful and debilitating complications.
Johnson R; McElhaney J; Pedalino B; Levin M
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S43-8. PubMed ID: 18162246
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
15. Varicella zoster vaccines.
Creed R; Satyaprakash A; Ravanfar P
Dermatol Ther; 2009; 22(2):143-9. PubMed ID: 19335725
[TBL] [Abstract][Full Text] [Related]
16. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
Holcomb K; Weinberg JM
J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
19. Herpes zoster and postherpetic neuralgia.
Johnson RW
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
[TBL] [Abstract][Full Text] [Related]
20. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
